About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ARWR
- Previous Close: $2.15
- 50 Day Moving Average: $1.96
- 200 Day Moving Average: $4.39
- 52-Week Range: $1.20 - $8.22
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.84
- P/E Growth: -0.59
- Market Cap: $160.32M
- Outstanding Shares: 74,569,000
- Beta: 2.08
- Net Margins: -1,663.58%
- Return on Equity: -89.07%
- Return on Assets: -64.08%
Companies Related to Arrowhead Pharmaceuticals:
- Debt-to-Equity Ratio: 0.03%
- Current Ratio: 2.87%
- Quick Ratio: 2.87%
What is Arrowhead Pharmaceuticals' stock symbol?
Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."
Where is Arrowhead Pharmaceuticals' stock going? Where will Arrowhead Pharmaceuticals' stock price be in 2017?
5 analysts have issued 1-year target prices for Arrowhead Pharmaceuticals' shares. Their predictions range from $1.00 to $2.00. On average, they expect Arrowhead Pharmaceuticals' share price to reach $1.80 in the next twelve months.
When will Arrowhead Pharmaceuticals announce their earnings?
Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 8th 2017.
Who owns Arrowhead Pharmaceuticals stock?
Arrowhead Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Silence Therapeutics Plc (9.21%), BlackRock, Inc (6.90%), State Street Corp (1.30%), Perceptive Advisors LLC (1.14%), Tudor Investment Corp Et Al (0.41%) and Charlemagne Capital Ltd. (0.14%). Company insiders that own Arrowhead Pharmaceuticals stock include Douglas B Given, Kenneth Allen Myszkowski and Mauro Ferrari.
Who sold Arrowhead Pharmaceuticals stock? Who is selling Arrowhead Pharmaceuticals stock?
Arrowhead Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp. Company insiders that have sold Arrowhead Pharmaceuticals stock in the last year include Douglas B Given and Kenneth Allen Myszkowski.
Who bought Arrowhead Pharmaceuticals stock? Who is buying Arrowhead Pharmaceuticals stock?
Arrowhead Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Tudor Investment Corp Et Al and Charlemagne Capital Ltd..
How do I buy Arrowhead Pharmaceuticals stock?
Shares of Arrowhead Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Arrowhead Pharmaceuticals stock cost?
One share of Arrowhead Pharmaceuticals stock can currently be purchased for approximately $2.15.